目的探讨体外修剪输尿管断端及置入双J管在腹腔镜下输尿管膀胱再植术中的可行性和有效性。方法回顾性分析2014年3月至2016年3月行腹腔镜输尿管膀胱再植术治疗的21例输尿管出口梗阻患者的资料。其中12例行常规腹腔镜输尿管膀胱再植术(对...目的探讨体外修剪输尿管断端及置入双J管在腹腔镜下输尿管膀胱再植术中的可行性和有效性。方法回顾性分析2014年3月至2016年3月行腹腔镜输尿管膀胱再植术治疗的21例输尿管出口梗阻患者的资料。其中12例行常规腹腔镜输尿管膀胱再植术(对照组),9例行腹腔镜配合体外操作输尿管膀胱再植术(改良组)。改良组患者均于腹腔镜下游离患侧输尿管,离断狭窄段输尿管,将近端输尿管沿12 mm Trocar孔拉出体外;直视下修剪输尿管断端并向输尿管内置入双J管,用4-0可吸收线将双J管固定在输尿管黏膜上,然后将其送入腹腔;在腹腔镜下游离膀胱,吻合膀胱和输尿管。结果 21例患者均顺利完成手术,无一例中转开放手术,术后均未发生漏尿。改良组患者手术时间短于对照组[(77±17)min vs (104±20)min,P<0.05]。21例患者术后随访半年,超声及静脉肾盂造影检查均提示无输尿管吻合口狭窄,肾积水不同程度减轻;膀胱造影提示有2例存在输尿管反流(对照组及改良组各1例)。结论在腹腔镜输尿管膀胱再植术中,应用体外修剪输尿管断端及置入双J管可在保证微创的前提下缩短手术时间、降低手术难度。展开更多
Background Tamsulosin hydrochloride can significantly improve benign prostatic hyperplasia （BPH） symptoms after the first dose and achieve long-term efficacy in European and American populations; however, the coresp...Background Tamsulosin hydrochloride can significantly improve benign prostatic hyperplasia （BPH） symptoms after the first dose and achieve long-term efficacy in European and American populations; however, the coresponding studies from China are rarely seen. The purpose of this study was to evaluate the long-term efficacy and safety of tamsulosin hydrochloride 0.2 mg once daily in patients with lower urinary tract symptoms （LUTS） suggestive of BPH in China. Methods Chinese patients with LUTS suggestive of BPH were enrolled in a 4-week placebo run-in period and subsequent 60-week open-label study. Tamsulosin hydrochloride 0.2 mg was administered daily during the period of the study. The efficacy and safety parameters were evaluated at the end of treatment period I （0-12 weeks） and period II （13-60 weeks）. The BPH patients were divided into tamsulosin monotherapy group and combination therapy group which received concomitant medication of finasteride 5 mg once daily after the evaluation at the end of treatment period I. Results A total of 113 patients were recruited to the study. Eighty-two patients received tamsulosin monotherapy and twenty-nine received combination therapy during the treatment period I1. Tamsulosin hydrochloride produced a great improvement in mean maximum urinary flow rate （Qmax） （1.7 ml/s, 3 ml/s） and a significant decrease in mean international prostate symptom score （IPSS） （4.1,6.4） after 12-week and 60-week treatments, respectively. At the end of treatment period II, there were significant improvement in IPSS, quality of life （QOL） score, Qmax and average flow rate （eave） for combination therapy group compared with the treatment period I （all P 〈0.05）. No serious adverse events （SAE） were recorded during the study. Conclusion Long-term tamsulosin hydrochloride therapy is a safe, effective and well-tolerated method for the treatment for LUTS suggestive of BPH in China.展开更多
文摘目的探讨体外修剪输尿管断端及置入双J管在腹腔镜下输尿管膀胱再植术中的可行性和有效性。方法回顾性分析2014年3月至2016年3月行腹腔镜输尿管膀胱再植术治疗的21例输尿管出口梗阻患者的资料。其中12例行常规腹腔镜输尿管膀胱再植术(对照组),9例行腹腔镜配合体外操作输尿管膀胱再植术(改良组)。改良组患者均于腹腔镜下游离患侧输尿管,离断狭窄段输尿管,将近端输尿管沿12 mm Trocar孔拉出体外;直视下修剪输尿管断端并向输尿管内置入双J管,用4-0可吸收线将双J管固定在输尿管黏膜上,然后将其送入腹腔;在腹腔镜下游离膀胱,吻合膀胱和输尿管。结果 21例患者均顺利完成手术,无一例中转开放手术,术后均未发生漏尿。改良组患者手术时间短于对照组[(77±17)min vs (104±20)min,P<0.05]。21例患者术后随访半年,超声及静脉肾盂造影检查均提示无输尿管吻合口狭窄,肾积水不同程度减轻;膀胱造影提示有2例存在输尿管反流(对照组及改良组各1例)。结论在腹腔镜输尿管膀胱再植术中,应用体外修剪输尿管断端及置入双J管可在保证微创的前提下缩短手术时间、降低手术难度。
文摘Background Tamsulosin hydrochloride can significantly improve benign prostatic hyperplasia （BPH） symptoms after the first dose and achieve long-term efficacy in European and American populations; however, the coresponding studies from China are rarely seen. The purpose of this study was to evaluate the long-term efficacy and safety of tamsulosin hydrochloride 0.2 mg once daily in patients with lower urinary tract symptoms （LUTS） suggestive of BPH in China. Methods Chinese patients with LUTS suggestive of BPH were enrolled in a 4-week placebo run-in period and subsequent 60-week open-label study. Tamsulosin hydrochloride 0.2 mg was administered daily during the period of the study. The efficacy and safety parameters were evaluated at the end of treatment period I （0-12 weeks） and period II （13-60 weeks）. The BPH patients were divided into tamsulosin monotherapy group and combination therapy group which received concomitant medication of finasteride 5 mg once daily after the evaluation at the end of treatment period I. Results A total of 113 patients were recruited to the study. Eighty-two patients received tamsulosin monotherapy and twenty-nine received combination therapy during the treatment period I1. Tamsulosin hydrochloride produced a great improvement in mean maximum urinary flow rate （Qmax） （1.7 ml/s, 3 ml/s） and a significant decrease in mean international prostate symptom score （IPSS） （4.1,6.4） after 12-week and 60-week treatments, respectively. At the end of treatment period II, there were significant improvement in IPSS, quality of life （QOL） score, Qmax and average flow rate （eave） for combination therapy group compared with the treatment period I （all P 〈0.05）. No serious adverse events （SAE） were recorded during the study. Conclusion Long-term tamsulosin hydrochloride therapy is a safe, effective and well-tolerated method for the treatment for LUTS suggestive of BPH in China.
